Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alexander Z Rivkin
OnabotulinumtoxinA for Treatment of Moderate-To-Severe Horizontal Lines and Glabellar Lines From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study
SKIN The Journal of Cutaneous Medicine
Related publications
OnabotulinumtoxinA Treatment of Moderate to Severe Glabellar Lines in Chinese Subjects After Laser Therapy: A Prospective, Open-Label, Noncomparative Study
Journal of Cosmetic and Laser Therapy
Dermatology
Medicine
Surgery
Efficacy and Patient Satisfaction With incobotulinumtoxinA for the Treatment of Glabellar Frown Lines
Singapore Medical Journal
Medicine
The Psychological Impacts of Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies
SKIN The Journal of Cutaneous Medicine
Efficacy and Safety of OnabotulinumtoxinA for Moderate-To-Severe Forehead Lines in Subjects With Upper Facial Lines
SKIN The Journal of Cutaneous Medicine
Onset, Longevity, and Patient Satisfaction With incobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Single-Arm, Prospective Clinical Study
Clinical Interventions in Aging
Medicine
Gerontology
Geriatrics
Patient-Reported Outcomes From Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)
SKIN The Journal of Cutaneous Medicine
Patient-Reported Outcomes in Moderate to Severe Hemophilia Patients: Finding From a Cross-Sectionalstudy in Korea
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician‐ and Patient‐Reported Satisfaction: Long‐Term Observational Results From the ASPIRE Study
PM and R
Physical Therapy
Sports Science
Sports Therapy
Neurology
Medicine
Rehabilitation
Patient-Reported Outcomes of Multiple Myeloma Patients Treated With Panobinostat After ≥2 Lines of Therapy Based on the International Phase 3, Randomized, Double-Blind, Placebo-Controlled PANORAMA-1 Trial
British Journal of Haematology
Hematology